MTOR Gene Function
Mechanistic Target of Rapamycin Kinase
Overview
mTOR integrates PI3K/AKT, amino acid, and energy signals through two distinct complexes: mTORC1 drives protein synthesis (S6K1, 4EBP1) and suppresses autophagy; mTORC2 phosphorylates AKT Ser473 for full activation. mTORC1 inhibitors (everolimus, temsirolimus) are approved in renal cell carcinoma, HR+ breast cancer, and pancreatic NETs, but paradoxically activate AKT through S6K1→IRS-1 feedback relief — limiting their single-agent efficacy. Catalytic mTOR inhibitors (gedatolisib) inhibit both complexes and avoid this paradox. TSC1/TSC2 loss in tuberous sclerosis drives constitutional mTORC1 hyperactivation; activating mTOR kinase mutations in ~5% of renal cell carcinoma may predict enhanced everolimus response.
Molecular Mechanism
Mechanism Summary
mTOR forms two structurally and functionally distinct complexes: mTORC1 (RAPTOR-containing) integrates PI3K/AKT, amino acid sufficiency, and energy signals to drive protein synthesis via S6K1 and 4EBP1 phosphorylation while suppressing autophagy; mTORC2 (RICTOR-containing) phosphorylates AKT Ser473 for full activation and PKCα for cytoskeletal control. mTORC1 inhibitors (everolimus, temsirolimus) are approved in renal cell carcinoma, HR+ breast cancer, and pancreatic NETs, but their utility is inherently constrained by paradoxical AKT reactivation through S6K1→IRS-1 negative feedback relief — the fundamental rationale for dual PI3K/mTOR catalytic inhibitors.
Step-by-Step Mechanism
RHEB-GTP directly contacts and activates mTORC1 (mTOR–RAPTOR–mLST8–PRAS40–DEPTOR) at the lysosomal membrane, where mTORC1 is held by the Ragulator–RAG GTPase complex in response to amino acid sufficiency.
Activated mTORC1 phosphorylates S6K1 at Thr389 in its hydrophobic motif. Activated S6K1 then phosphorylates rpS6, eIF4B, and SKAR to promote mRNA translation, ribosome biogenesis, and splicing of growth-factor mRNAs.
mTORC1 phosphorylates 4EBP1 at multiple sites (Thr37/46, Ser65, Thr70), releasing eIF4E from 4EBP1 inhibition. Free eIF4E assembles the eIF4F cap-binding complex, enabling cap-dependent translation of 5′-TOP mRNAs (ribosomal proteins, translation factors).
mTORC1 suppresses autophagy by phosphorylating ULK1 at Ser757, preventing AMPK-mediated ULK1 activation. This stops the ULK1–ATG13–FIP200 autophagy-initiation complex from assembling.
mTORC2 (mTOR–RICTOR–mSin1–mLST8) phosphorylates AKT Ser473 (full activation), PKCα (cytoskeletal organisation), and SGK1 (ion transport, FOXO regulation) — acting as a positive feedback amplifier of PI3K signalling.
S6K1 activated by mTORC1 phosphorylates IRS-1 at inhibitory serine residues, reducing PI3K recruitment to insulin receptor — a negative feedback loop that limits mTORC1 activity but paradoxically activates AKT when mTORC1 is inhibited by rapamycin.
Upstream Regulators
Direct mTORC1 activator at lysosomal surface; activated when TSC1/TSC2 is inhibited by AKT
Recruit mTORC1 to lysosome in response to amino acid sufficiency; RAGA/B-RAGC/D heterodimers
Energy sensor; activates TSC2 and phosphorylates RAPTOR to inhibit mTORC1 under low ATP
Downstream Targets
mRNA translation, ribosome biogenesis, splicing
eIF4E release; cap-dependent translation activation
Autophagy suppression
Full AKT activation; FOXO inhibition
Key Post-Translational Modifications
mTORC2 intrinsic kinase activity marker
Positive autoregulatory loop
Disease Mechanism
mTOR signalling can increase through upstream PI3K/AKT activation, PTEN loss, TSC1/TSC2 loss or less common MTOR alterations. Allosteric rapalogs predominantly inhibit mTORC1, while mTORC2 and upstream signalling may remain active; relief of S6K–IRS feedback can also restore pathway input in some contexts. Catalytic mTOR and combined PI3K/mTOR strategies aim to broaden pathway suppression but have agent- and disease-specific evidence. An MTOR variant should be interpreted by allele and tumour context rather than assumed to predict inhibitor response.
Database References
Key Pathways
- ·mTOR signaling
- ·PI3K-AKT-mTOR
- ·Autophagy suppression
- ·Amino acid sensing
- ·mTOR inhibitor resistance
Disease Associations
- ·Tuberous sclerosis
- ·Renal cell carcinoma
- ·HR+ breast cancer
- ·Pancreatic neuroendocrine tumours
Research Activity
MTOR is an actively studied target: about 75+ clinical trials that mention it are currently recruiting on ClinicalTrials.gov. Trial activity reflects research interest, not proven benefit — designs, endpoints and populations vary widely.
Track MTOR trials
New and changed oncology trials, summarised in plain language each day.
Functional Partners
Common Questions About MTOR
What does mTOR do?
mTOR is a serine/threonine kinase that forms two distinct complexes: mTORC1 drives protein synthesis (via S6K1 and 4EBP1), ribosome biogenesis, and lipid synthesis while suppressing autophagy; mTORC2 phosphorylates and activates AKT at Ser473 and regulates cytoskeletal organisation.
What cancers respond to mTOR inhibitors?
Everolimus is an allosteric mTORC1 inhibitor with indication-specific regulatory uses. Inhibiting mTORC1 can relieve S6K–IRS1 negative feedback and increase upstream signalling in some models, while mTORC2 may remain active. These observations motivate broader pathway-inhibition strategies but do not establish a universal resistance mechanism or treatment combination.
What is tuberous sclerosis and mTOR?
Tuberous sclerosis complex (TSC) is caused by germline mutations in TSC1 or TSC2, which encode the hamartin-tuberin complex that acts as a GAP for the small GTPase RHEB. Loss of TSC1/TSC2 causes constitutive RHEB-mediated mTORC1 activation, driving benign hamartoma growth in kidney, brain, lung, and skin.
Why do mTOR inhibitors paradoxically activate AKT?
When mTORC1 is inhibited by rapalogs (everolimus, temsirolimus), active S6K1 is suppressed. S6K1 normally phosphorylates IRS-1 at inhibitory serine residues, reducing IRS-1's ability to activate PI3K downstream of insulin and IGF1 receptors. When S6K1 is suppressed, IRS-1 dephosphorylation restores its activating function, leading to increased PI3K→PDK1→AKT Thr308 phosphorylation. Simultaneously, mTORC2 (not inhibited by rapalogs) continues to phosphorylate AKT Ser473 for full activation. The net result is elevated AKT activity during mTORC1 inhibition — the opposite of the intended effect — which limits the apoptotic response and is a key reason mTORC1 inhibitors have modest single-agent efficacy. Catalytic mTOR inhibitors (INK128, gedatolisib) inhibit both complexes and avoid this paradox.
What is the difference between rapalogs and catalytic mTOR inhibitors?
Rapalogs (everolimus, temsirolimus) are allosteric inhibitors that bind FKBP12 and the FKBP12-rapamycin binding domain of mTOR, sterically preventing RAPTOR from positioning substrates for mTORC1 phosphorylation — they inhibit mTORC1 but not mTORC2. Catalytic (ATP-competitive) mTOR inhibitors (INK128/sapanisertib, gedatolisib) bind the mTOR kinase catalytic site in both mTORC1 and mTORC2, blocking all mTOR kinase activity simultaneously. Catalytic inhibitors therefore also suppress mTORC2→AKT Ser473 phosphorylation, avoiding the paradoxical AKT activation that limits rapalogs. However, they have broader toxicity profiles and the superior therapeutic index expected from complete mTOR blockade has not always translated clinically.
Which cancers have activating mTOR kinase mutations and can they be targeted?
Activating mTOR kinase domain mutations occur in ~5% of clear cell renal cell carcinoma (most prominently E2014K, E2419K, L2427Q in the kinase domain FATC region), ~7% of bladder cancer, and occasionally in endometrial and breast cancer. These mutations create constitutive mTOR kinase activity independent of upstream RHEB-GTP input. Retrospective analyses suggest that renal cell carcinoma patients with activating mTOR mutations derive superior benefit from everolimus compared to wild-type mTOR tumours — consistent with oncogene addiction to mTOR kinase activity. This represents an emerging molecular biomarker for mTOR inhibitor selection, though prospective validation in dedicated biomarker-selected trials is ongoing.